Table 1.

Economic evaluation characteristics.

Decision Problem	What is the Relative Cost-Effectiveness of Strategies to Identify Lynch Syndrome in Women with Endometrial Cancer
Interventions and comparators	Strategy 0: No testing Strategy 1: MSI triage followed by NGS Strategy 2: MSI and MLH1 methylation testing triage followed by NGS Strategy 3: IHC and MLH1 methylation testing triage followed by NGS (the Manchester approach) Strategy 4: Direct NGS
Type of economic evaluation, costs, and health outcomes	Cost-effectiveness analysis: Diagnostic costs and Lynch syndrome cases identified (no cost-effectiveness threshold identified) Cost-utility analysis: Lifetime costs and QALYs for women with endometrial cancer and their relatives (cost-effectiveness threshold £20,000 per QALY)
Model type	Decision tree and Markov model implemented in R
Key data source	PETALS study (diagnostic accuracy study conducted in Manchester)
Perspective	NHS and PSS, costs in pounds sterling (£; GBP) in 2016/17 prices
Time horizon	Lifetime
Discounting	3.5% for costs and QALYs
Analysis of uncertainty	Non-parametric bootstrap resampling of participants in a clinical study and parametric sampling of model parameters (probabilistic sensitivity analysis)

MSI: microsatellite instability; IHC: immunohistochemistry; NGS: next generation sequencing; QALY: quality-adjusted life years; PETALS: The Proportion of Endometrial Tumours Associated with Lynch Syndrome; NHS: National Health Service; PSS: personal social services; GBP: (Great British) Pounds sterling (£).